ARS Pharmaceuticals Ownership | Who Owns ARS Pharmaceuticals?


OverviewForecastRevenueFinancialsChartTranscripts

ARS Pharmaceuticals Ownership Summary


ARS Pharmaceuticals is owned by 77.71% institutional investors, 21.14% insiders, and 1.15% retail investors. Ra capital management is the largest institutional shareholder, holding 11.19% of SPRY shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.20% of its assets in ARS Pharmaceuticals shares.

SPRY Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockARS Pharmaceuticals77.71%21.14%1.15%
SectorHealthcare Stocks 279.19%10.58%-189.76%
IndustryBiotech Stocks 63.97%10.68%25.35%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Ra capital management10.86M11.19%$114.58M
Deerfield management company, l.p. (series c)10.51M10.84%$110.93M
Orbimed advisors8.29M8.54%$87.44M
Blackrock funding, inc. /de4.57M4.71%$48.26M
Sr one capital management, lp4.01M4.14%$42.34M
Alliancebernstein3.88M4.00%$40.94M
Vanguard group3.46M3.57%$36.56M
Franklin resources1.98M2.04%$20.85M
Alyeska investment group1.25M1.29%$13.23M
Geode capital management1.24M1.28%$13.07M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Sr one capital management, lp4.01M10.32%$42.34M
Deerfield management company, l.p. (series c)10.51M2.10%$110.93M
Orbimed advisors8.29M1.81%$87.44M
Nextech invest936.73K1.60%$9.88M
Ra capital management10.86M1.52%$114.58M
First turn management593.29K1.12%$6.26M
Sectoral asset management106.01K0.75%$1.12M
Wexford capital lp369.50K0.62%$3.90M
Levin capital strategies467.63K0.47%$4.93M
Valley forge investment consultants inc adv83.22K0.30%$878.02K

Top Buyers

HolderShares% AssetsChange
Alliancebernstein3.88M0.01%3.81M
Alyeska investment group1.25M0.05%1.13M
Ubs group1.01M0.00%902.82K
Raymond james financial623.28K0.00%623.28K
Goldman sachs group886.12K0.00%610.26K

Top Sellers

HolderShares% AssetsChange
Franklin resources1.98M0.01%-860.84K
Deerfield management company, l.p. (series c)10.51M2.10%-563.27K
Duquesne family office---536.90K
Price t rowe associates inc /md/19.92K--442.60K
Eam investors---261.65K

New Positions

HolderShares% AssetsChangeValue
Raymond james financial623.28K0.00%623.28K$6.58M
Cormorant asset management, lp500.00K0.29%500.00K$5.28M
Peregrine capital management423.56K0.13%423.56K$4.47M
Bank of montreal /can/340.59K0.00%340.59K$3.59M
Sei investments108.27K0.00%108.27K$1.14M

Sold Out

HolderChange
National bank of canada /fi/-1.00
Eversource wealth advisors-5.00
Srs capital advisors-22.00
Capital performance advisors llp-33.00
Nelson, van denburg & campbell wealth management group-50.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 20251888.05%76,205,3346.92%771.44%992.06%5420.00%
Dec 31, 20241641.23%68,247,8906.54%701.61%88-14.56%4469.23%
Sep 30, 202416235.00%64,056,6692.41%661.58%10351.47%268.33%
Jun 30, 20241201.69%62,551,0554.44%641.68%683.03%24-4.00%
Mar 31, 202411812.38%59,892,346-8.46%621.35%6637.50%25-16.67%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv2.16M2.20%63.34K
Vanguard US Total Market Shares ETF1.86M1.90%-
iShares Russell 2000 ETF1.26M1.28%615.00
Franklin Biotechnology Discv A(acc)USD1.17M1.20%-
AB Small Cap Growth A1.17M1.19%5.11K
Fidelity Select Biotechnology971.26K0.99%-40.80K
MEDICAL BioHealth EUR Acc909.27K0.93%219.06K
SPDR® S&P Biotech ETF849.94K0.87%1.10K
Vanguard Institutional Extnd Mkt Idx Tr809.88K0.82%1.09K
AB Discovery Growth A801.96K0.82%16.09K

Recent Insider Transactions


DateNameRoleActivityValue
May 20, 2025Fitzpatrick Alexander A Chief Legal OfficerSell$1.45M
May 20, 2025SAUNDERS BRENT L-Sell$1.71M
May 20, 2025Scott Kathleen D. Chief Financial OfficerSell$705.16K
Apr 07, 2025Shawver Laura-Sell$615.07K
Mar 20, 2025Karas Eric Chief Commercial OfficerSell$140.00K

Insider Transactions Trends


DateBuySell
2025 Q2-4
2025 Q1-5
2024 Q4-58
2024 Q3-51
2024 Q2-32

SPRY Ownership FAQ


Who Owns ARS Pharmaceuticals?

ARS Pharmaceuticals shareholders are primarily institutional investors at 77.71%, followed by 21.14% insiders and 1.15% retail investors. The average institutional ownership in ARS Pharmaceuticals's industry, Biotech Stocks , is 63.97%, which ARS Pharmaceuticals exceeds.

Who owns the most shares of ARS Pharmaceuticals?

ARS Pharmaceuticals’s largest shareholders are Ra capital management (10.86M shares, 11.19%), Deerfield management company, l.p. (series c) (10.51M shares, 10.84%), and Orbimed advisors (8.29M shares, 8.54%). Together, they hold 30.57% of ARS Pharmaceuticals’s total shares outstanding.

Does Blackrock own ARS Pharmaceuticals?

BlackRock is not among the top 10 institutional shareholders of ARS Pharmaceuticals.

Who is ARS Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Sr one capital management, lp is ARS Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 10.32% of its assets in 4.01M ARS Pharmaceuticals shares, valued at 42.34M$.

Who is the top mutual fund holder of ARS Pharmaceuticals shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of ARS Pharmaceuticals shares, with 2.20% of its total shares outstanding invested in 2.16M ARS Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools